Correspondence on Letter regarding "Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF-κB signaling pathways"

Clin Mol Hepatol. 2023 Jan;29(1):171-172. doi: 10.3350/cmh.2022.0381. Epub 2022 Nov 10.
No abstract available

Keywords: Auranofin; Ferroptosis; Hepatocellular carcinoma; Non-alcoholic fatty liver disease.

Publication types

  • Letter
  • Comment

MeSH terms

  • Auranofin* / therapeutic use
  • Fibrosis
  • Humans
  • Liver / pathology
  • Liver Cirrhosis* / drug therapy
  • Liver Cirrhosis* / etiology
  • Liver Cirrhosis* / pathology
  • NF-E2-Related Factor 2
  • NF-kappa B / metabolism
  • Non-alcoholic Fatty Liver Disease* / complications
  • Non-alcoholic Fatty Liver Disease* / drug therapy
  • Non-alcoholic Fatty Liver Disease* / pathology
  • Signal Transduction

Substances

  • Auranofin
  • NF-E2-Related Factor 2
  • NF-kappa B